Thermo Fisher Scientific is expanding its life sciences portfolio by acquiring a division of Solventum that provides technologies and products used in the manufacturing of biologic drugs. Under deal ...

FY’24 results showcase growth potential with 12% IRR, strategic acquisitions, and undervalued stock. Read more on TMO stock ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

Thermo Fisher Scientific CIO Ryan Snyder believes business strategy and tech strategy should be woven together and that data ...

Explore Thermo Fisher Scientific Inc.'s valuation, modest growth challenges, and recent M&A moves. Click for my updated look ...

Citi lowered the firm’s price target on Thermo Fisher (TMO) to $570 from $650 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the ...

The addition of Solventum’s business provides a strategic fit with Thermo Fisher and will create value for customers, ...

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) had its price target reduced by research analysts at Citigroup from ...

February 19, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE ... Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing ...

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue ...

Thermo Fisher Scientific agreed to acquire Solventum's purification and filtration business for $4.1 billion in cash, confirming a report first made in The Wall Street Journal.

Once the transaction closes, Solventum’s Purification & Filtration business will become part of Thermo Fisher's Life Sciences Solutions segment. Solventum’s Purification & Filtration ...